Advanced searches left 3/3

Multiple Myeloma - Wiley Online Library

Summarized by Plex Scholar
Last Updated: 13 May 2022

* If you want to update the article please login/register

One‐Year Comparison of Body Composition in a Cohort of Patients with Multiple Myeloma

In a cohort of patients with multiple myeloma, we wanted to see if there has been any changes in body fat composition and skeletal muscle density over a one-year period. Hypothesis In a one-year follow-up for patients with multiple myeloma, we hypothesized that there are differences in specific body fat composition and skeletal muscle indices. Methods This is a retrospective cohort study looking at preexisting CT scans of multiple myeloma patients from a midwestern healthcare system. One investigator using Aquarius iNtuition software version 4. 12 performed body fat and skeletal muscle measurements. Slices were taken at the third lumbar vertebrae, where both transverse processes were apparent, to standardize the CT scan results. Results Anonymous patients with MM were found to have had two complete body low-dose CT scans one year before the study period. The mean visceral adipose tissue volume and the subcutaneous adipose tissue area in women increased marginally from baseline to the one-year follow-up. The mean skeletal muscle mass density increased from baseline to follow-up, which was barely different from baseline to follow-up. From baseline to one-year follow-up, men also showed a marginal reduction in visceral tissue volume and the subcutaneous adipose tissue area. Multiple myeloma patients' body fat composition and muscle density changed over a one-year period, and we did a retrospective review. “Adipose Tissue Radiodensity in People with Multiple Myeloma: A New Prognostic Biomarker in People with Multiple Myeloma” Nutrition, vol.

Source link: https://onlinelibrary.wiley.com/doi/10.1096/fasebj.2022.36.S1.0R733


Diabetes mellitus and multiple myeloma; common features of two distinct entities

In people with type 2 DM, cardiovascular disease was the leading cause of morbidity in type 2 DM, but a shift from cardiovascular disease to cancer as the leading contributor to DM-related death has been observed lately. The presence of DM may have a determinant effect on both the safety and the adverse effects of antimyeloma therapy. Metformin could have a synergistic effect with antimyeloma drugs while also reducing some of the drug's adverse effects; pioglitazone may have beneficial results if used as an add on therapy in patients with relapsed or refractory MM. No clinically significant interactions have been found between antidiabetic drugs and the most commonly used antimyeloma drugs. Patients with MM are strongly advised that a baseline investigation of risk factors for glucose intolerance and close monitoring of glucose levels during therapy is strongly recommended.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/dmrr.3535


Dissecting the Impact of Bromodomain Inhibitors on the IRF4‐MYC Oncogenic Axis in Multiple Myeloma

Multiple myeloma, a commonly incurable plasma cell malignancy, is a leading cause in the pathogenesis and progression of the disease and progression of multiple myeloma. Targeting the IRF4-MYC oncogenic loop has the ability to develop a selective and safe therapy for MM. Although all inhibitors triggered cell death, we found no synergistic advantage of affecting both of these regulators on the viability of MM cell lines. We found reduced IRF4 protein expression or mRNA levels of downstream target genes for all inhibitors over a time period up to 72 hours, but not a drastic decrease in IRF4 protein expression or mRNA levels of downstream target genes. IRF4 protein in MM cells had a long half-life, according to a further investigation. These findings indicate that bromodomain inhibitors are not effective in killing IRF4 in MM and that novel therapeutic approaches should concentrate on the direct inhibition or degradation of IRF4 in MM.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/hon.3016


Real‐world data on prognostic value of measurable residual disease assessment by fragment analysis or next‐generation sequencing in multiple myeloma

Nevertheless, the limited availability of MRD testing in daily clinical use has hampered its optimal use of MRD in daily clinical practice. We therefore examined the clinical relevance of commercially available MRD modalities based on fragment analysis with IdentiClone® and next-generation sequencing with LymphoTrack® in newly diagnosed patients with autologous stem cell transplantation in newly diagnosed patients with MM who underwent autologous stem cell transplantation. We demonstrate the feasibility and clinical benefit of achieving MRD negativity by commercially available clonality-based MRD assays in MM and support that incorporate NGS, but not fragment analysis, to develop therapeutic guidelines in real-world context.

Source link: https://onlinelibrary.wiley.com/doi/10.1111/bjh.18211


Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial

Patients with a patient with a difficult/refractory multiple myeloma are unmet need. Patients received bentamustine 120 mg/m2 days 1–21, pomalidomide 3 mg days 1–21, and dexamethasone 40 mg days 1, 8, 22, a maximum of six cycles. Both lenalidomide and bortezomib were refractory to patients with a median of three previous lines and 87% were refractory to both lenalidomide and bortezomib. The main end-point was the overall response rate, which was described as a partial response after at least three cycles. ' Patients with extraductlary myeloma had a higher response rate.

Source link: https://onlinelibrary.wiley.com/doi/10.1111/bjh.18200


Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results

Multiple doses of ibrutinib in combination with standard doses of lenalidomide and dexamethasone were tested in RRMM patients by a standard 3+3 design. In combination with lenalidomide and dexamethasone, the primary aim was to determine the maximum tolerated dose of ibrutinib. MTD of ibrutinib was 800 mg and just 1 dose restricting toxicity; a grade 3 rash possibly related to ibrutinib was reported. In 2, lymphopenia in two, lymphopenia in two, leukopenia, neutropenia, thrombocytopenia, and anemia were among the most common grade 3 adverse events, which were observed in three patients each.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/hon.3012


CAR‐T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status

In this open-label, single-arm phase I/II clinical trial, 49 relapsed/refractory multiple myeloma patients, including 20 with Eastern Cooperative Oncology Group grade 3–4, were tested for the effectiveness of antiB cell maturation antigen chimeric antigen receptor T cell therapy. PFS was 15 months and 4 months, respectively, in patients with ECOG 0–2 and 3–4, ORR was 79. 31% and 75%. In ECOG 0–2 patients, OS was not established, but in ECOG 3–4 patients, it was 10. 5 months. Hence, HDS269B therapy is safe and effective for RRMM patients, as well as those with ECOG 3–4.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/ajh.26583


Overexpression of the energy metabolism transcriptome within clonal plasma cells is associated with the pathogenesis and outcomes of patients with multiple myeloma

In the clonal plasma cells isolated from patients with newly diagnosed multiple myeloma and oxidative phosphorylation, the expression of specific genes associated with the production of various enzymes and proteins involved in glycolysis and oxidative phosphorylation was investigated in the Multiple Myeloma research Foundation CoMMpass data set was determined. Patients with NDMM had poor progression free survival and overall survival rates, according to this EMMS report. Patients with monoclonal gammopathy of undetermined severity were more likely to be present in clonal plasma cells isolated from Multiple myeloma patients than those from patients with monoclonal gammopathy of undetermined severity. This was scientifically established by MM patients' clonal plasma cells from a higher rate of mitochondrial and glycolysis-derived ATP formation than MGUS patients' clonal plasma cells. This research provides evidence for the role of energy metabolism in clonal plasma cells on pathogenesis and survival of patients with MM.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/ajh.26577

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions